Veliparib

Drug Profile

Veliparib

Alternative Names: ABT-888; NSC-737664

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Abbott Laboratories; University of Alabama at Birmingham
  • Developer Abbott Laboratories; AbbVie; Georgetown University; Narodny onkologicky ustav; National Cancer Institute (USA); University of Alabama at Birmingham
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours
  • Phase I/II Small cell lung cancer
  • Phase I Prostate cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 02 Mar 2017 Northwestern University, Bristol-Myers Squibb, AbbVie and National Cancer Institute plan a phase I trial for Solid tumours and Lymphoma (Late-stage disease, Combination therapy) in USA (NCT03061188)
  • 13 Feb 2017 AbbVie plans a phase II trial for Cancer in Netherlands (NCT03044795)
  • 23 Jan 2017 The University of Texas Health Science Center plans a phase II trial in Breast cancer and Ovarian Cancer (Late stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (NCT03032614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top